Angelo S. Botter
Nessuna posizione attualmente
Profilo
Angelo S.
Botter worked as a Director at Advanced Viral Research Corp.
from 2006 to 2009 and at Medexus Pharmaceuticals, Inc. from 2013 to 2014.
He obtained an undergraduate degree from McGill University.
Precedenti posizioni note di Angelo S. Botter
| Società | Posizione | Fine |
|---|---|---|
| MEDEXUS PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 02/06/2014 |
Advanced Viral Research Corp.
 Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Direttore/Membro del Consiglio | 23/03/2009 |
Formazione di Angelo S. Botter
| McGill University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| MEDEXUS PHARMACEUTICALS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Advanced Viral Research Corp.
Advanced Viral Research Corp. Pharmaceuticals: MajorHealth Technology Advanced Viral Research Corp. is a biopharmaceutical company, engages in the research, development, and commercialization of small molecule therapeutics that address medical needs for various degenerative conditions. Its products include AVR118, a cytoprotective drug composed of a complex mixture of protein and ribonucleic acid components; AVR123, a form of AVR118 specially designed for dermatology applications, which is in Phase II clinical trials; AVR147, an inhibitor of a cancer target known as a proteasome; AVR168 that is a natural product, which inhibits a member of a family of motor proteins that are responsible for the assembly and function of microtubules during cell division. The company was founded in July 1985 and is headquartered in Yonkers, NY. | Health Technology |
- Borsa valori
- Insiders
- Angelo S. Botter
